--- title: "Hong Kong Stock Movement: PEGBIO CO-B plummets 24.62%, with clear capital flow, volatility attracts market attention" type: "News" locale: "en" url: "https://longbridge.com/en/news/286368483.md" description: "PEGBIO CO-B fell 24.62%; CanSino Biologics dropped 3.06%, with a transaction volume of HKD 809 million; Innovent Biologics decreased by 1.67%, with a transaction volume of HKD 659 million; Genscript Biotech rose 8.07%, with a transaction volume of HKD 460 million; BeiGene fell 2.50%, with a market value of HKD 282.4 billion" datetime: "2026-05-14T06:26:45.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286368483.md) - [en](https://longbridge.com/en/news/286368483.md) - [zh-HK](https://longbridge.com/zh-HK/news/286368483.md) --- # Hong Kong Stock Movement: PEGBIO CO-B plummets 24.62%, with clear capital flow, volatility attracts market attention **Hong Kong Stock Movement** PEGBIO CO-B, down 24.62%, with no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. **Stocks with High Trading Volume in the Industry** Kangfang Biotech, down 3.06%, with a trading volume of HKD 809 million, and no significant news recently. Trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics down 1.67%. Based on recent key news: 1. On May 12, JP Morgan published a research report indicating that the drug catalog adjustment plan announced by the National Healthcare Security Administration will improve the commercialization prospects for innovative drug developers. Innovent Biologics is listed as an industry preferred stock, with expectations for faster sales growth and improved revenue visibility driving stock price volatility. Source: JP Morgan 2. On May 11, Innovent Biologics received breakthrough therapy designation from China's NMPA for the combination treatment of IBI363 and bevacizumab for colorectal cancer patients. This designation brings positive impacts to the company, causing stock price volatility. Source: Innovent Biologics announcement 3. On May 11, BeiGene's BTK inhibitor saw significant global sales, with a substantial increase in external licensing transactions within the industry, driving overall volatility in the innovative drug sector. Source: Industry report on the investment logic shift in the innovative drug sector towards profit verification. Jitai Technology-P up 8.07%. Based on recent key news: 1. On May 13, Jitai Technology debuted, with the opening price rising 173.1% from the listing price, and the total trading volume reaching HKD 2.403 billion, showing high market attention to its AI nanomaterials innovation platform. Source: Zhitong Finance 2. On May 13, Jitai Technology performed strongly in the dark market, with the closing price up 180% from the offering price, reflecting investor confidence in its technology platform and product pipeline. Source: Economic Information Agency 3. On May 13, Jitai Technology's public offering was oversubscribed 6,909 times, indicating strong market demand for its AI drug delivery technology. Source: Huigang Communications, high attention in the AI pharmaceutical field, with evident capital inflow. **Stocks with High Market Capitalization in the Industry** BeiGene down 2.50%. Based on recent news: 1. On May 11, BeiGene released its Q1 2026 performance report, showing the company achieved operating revenue of RMB 10.544 billion, a year-on-year increase of 31%; net profit attributable to the parent company was RMB 1.608 billion, turning from loss to profit year-on-year. The performance change is mainly due to product revenue growth and expense management driving operational efficiency improvements. This news provides positive support for the stock price. 2. On May 12, BeiGene's stock closed at HKD 190.5, with an intraday fluctuation of over 4%, and a trading volume of HKD 748 million. Technical analysis shows that the MACD daily line formed a golden cross signal above the zero axis, indicating that bullish momentum is gathering again in the previous upward trend. On the news front, the global biotechnology sector has recently gained continuous attention, and BeiGene, as one of the most internationalized Chinese innovative pharmaceutical companies, still has significant expectations for the growth of its core pipeline in overseas markets, which remains an important logic for institutional layout On May 13th, BeiGene announced that its new drug Baiyueda® (sotatercept, BEQALZI™) has received accelerated approval from the U.S. FDA for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. This news creates positive expectations for the company's future performance growth. The Hong Kong stock market's pharmaceutical sector is overall active, and attention should be paid to the accompanying trading volume ### Related Stocks - [02565.HK](https://longbridge.com/en/quote/02565.HK.md) - [09926.HK](https://longbridge.com/en/quote/09926.HK.md) - [01801.HK](https://longbridge.com/en/quote/01801.HK.md) - [07666.HK](https://longbridge.com/en/quote/07666.HK.md) - [06160.HK](https://longbridge.com/en/quote/06160.HK.md) ## Related News & Research - [Some May Be Optimistic About Coloplast's (CPH:COLO B) Earnings](https://longbridge.com/en/news/287005062.md) - [NorthPalm Capital Launches as AI-Augmented Investment Company | SCYRF Stock News](https://longbridge.com/en/news/286914222.md) - [Dream Unlimited Corp. Announces Quarterly Class a Subordinate Voting Share and Class B Common Share Dividend](https://longbridge.com/en/news/287086466.md) - [Release according to article 135 section 2 BörseG](https://longbridge.com/en/news/286754366.md) - [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)